³ëµ¿¿µ ¹Ú»ç Q&A
¹Ú»ç´Ô »ó´ãÄÚ³Ê
¹Ú»ç´Ô ¾à·Â
ºñ³Ê½º Ä®·³
ÀÚÁÖ¹¯´Â Áú¹®
¹Ú»ç´Ô »ó´ãÄÚ³Ê
Àǽɽº·¯¿î Áõ»óÀ̳ª, ¼ö¼ú ÀüÈÄÀÇ ÈÄÀ¯Áõ µî ±Ã±ÝÇÏ°í ´ä´äÇÑ °í¹Î°Å¸®¸¦ ³ëµ¿¿µ ¹Ú»ç´ÔÀÌ Á÷Á¢ »ó´ãÇØ µå¸³´Ï´Ù.
ÀÚ½ÅÀÇ °í¹Î°ú ºñ½ÁÇÑ ´Ù¸¥ »ç¶÷ÀÇ ±Û·Îµµ ÇÑ´«¿¡ ¾Ë±â ½±µµ·Ï Q&A°¡ µµ¿Íµå¸± °ÍÀÔ´Ï´Ù.
´äº¯Æ¯ÀÌÄÉÀ̽º À¯¹æ¾ÏÀ̶ó°í Çؼ­ Áú¹®µå¸³´Ï´Ù
ÀÛ¼ºÀÚ : ³ëµ¿¿µ ÀÛ¼ºÀÏ : 2024-04-03 [07:19]Á¶È¸ : 368
³×, ƯÀÌÇÏ´Ù´Â °ÍÀÌ À§Ä¡°¡ ƯÀÌÇÏ´Ù´Â ¶æ °°Àºµ¥
±«»óÇÑ ³ðÀº ¾Æ´Ï°í,¾ÆÁÖ Æò¹üÇÏ°í ³·Àº ´Ü°èÀÇ ¾ÏÀ̾î¿ä
¹°·Ð Àú´Â Á¾Á¾ º¸¾ÒÁö¿ä, Ưº°ÇÑ À§Ä¡ÀÌ´Ù. ±×·± ¶æÀÌ°í
±× ºÐÀÇ °èȹÀÌ ¸Â¾Æ¿ä. ±×¸® ¹Þµµ·Ï ¸¾ ÆíÈ÷ÇÏ¸é µÇ¿ä



¾Æ¸®¼Û ´Ô ¿ø¹®³»¿ë

ƯÀÌÄÉÀ̽º À¯¹æ¾ÏÀ̶ó°í Çؼ­ Áú¹®µå¸³´Ï´Ù

¾È³çÇϼ¼¿ä ±³¼ö´Ô
Àú´Â °Üµå¶ûÀÌ °¡¿îµ¥ 1¼¾Ä¡ Á¤µµÀÇ ¸Û¿ïÀÌ ÀâÇô¼­ °³ÀÎ º´¿ø¿¡¼­ Ç¥Áö³¶Á¾À¸·Î Áø·á¸¦ ¹Þ°í ¸Û¿ïÀ» ¶¼¾î³»´Â ¼ö¼úÀ» ¹ÞÀº ÈÄ Á¶Á÷°Ë»ç¸¦ Çߴµ¥ È£¸£¸ó ¾ç¼º À¯¹æ¾Ï Áø´ÜÀ» ¹Þ¾Ò½À´Ï´Ù
¤·¤¸´ëÇб³ º´¿ø¿¡¼­ ¼ö¼ú Àü °Ë»ç¸¦ ¹Þ°í ´ã´ç ±³¼ö´ÔÀ» ¸¸³µ´Âµ¥ »À,¸²ÇÁ¿Í ´Ù¸¥ Àå±â´Â ÀüÀÌ°¡ ¾øÀ½À» À̾߱â ÇÏ¼Ì°í º´±â´Â 1±â Á¤µµ·Î ÆÇ´ÜÇϼ̽À´Ï´Ù
´ã´ç ±³¼ö´Ô ¸»¾¸À¸·Ð °Üµå¶ûÀÌ¿¡¼­ À¯¹æ¾ÏÀ» ¹ß°ßÇÑ »ç·Ê°¡ ±ØÈ÷ µå¹°´Ù´Â À̾߱⸦ Çϼ̰í, ¼ö¼ú ½Ã °Üµå¶ûÀÌ Á¶Á÷ ºÎºÐ¿¡ ÀÖ´Â Á¤»ó Á¶Á÷À» ´õ ¶¼¾î³»¼­ °æ°è ºÎºÐ¿¡ ¾ÏÀÌ ÀÖ´ÂÁö Á¤È®ÇÑ º´±â¸¦ È®ÀÎÇÏÀÚ°í Çϼ̽À´Ï´Ù

±³¼ö´Ôµµ Àú¿Í °°Àº »ç·ÊÀÇ À¯¹æ¾Ï ȯÀÚ¸¦ º¸½ÅÀûÀÌ ÀÖÀ¸½Å°¡¿ä?
ƯÀÌÄÉÀ̽º¶ó´Â ¸»¾¸À» Çϼż­ ¼ö¼ú¿¡ °üÇÑ ±³¼ö´ÔÀÇ »ý°¢À» µé¾îº¸°í ½Í¾î¼­ ÀÌ·¸°Ô Áú¹®µå¸³´Ï´Ù

¾Æ·¡´Â Á¶Á÷º´¸® °á°ú ¼öÄ¡ÀÔ´Ï´Ù.

º´¸®ÇÐÀû Áø´Ü:À¯¹æ, ¿ÞÂÊ, ÀýÁ¦: Ư¼ö À¯ÇüÀÌ ¾Æ´Ñ ħÀ±¼º À¯°ü¾Ï(Invasive carcinoma of no special type, ductal)Å©±â: ¾à 12x11mmºÎÀ§: °Üµå¶ûÀÌ
ÇÙ µî±Þ(Nuclear grade): 2 (Áß°£µµ ºÐÈ­)
Á¶Á÷ÇÐÀû µî±Þ(Histologic grade, Nottingham Histologic score): 1+1+1=3 (Á¡¼ö 6)
¼¼°ü Çü¼º(Tubule formation): 1
ÇÙ´ÙÇü¼º(Nuclear pleomorphism): 1
ºÐ¿­·ü(Mitotic rate): 1
»óÇdz»¾Ï(EIC) Á¸Àç: ¾øÀ½(EIC negative)
ÀýÁ¦ °æ°è(Resection margins): È®ÀÎ ºÒ°¡
¸²ÇÁ°ü ħ½À(Lymphovascular invasion): Á¸Àç
½Å°æÁÖº¯ ħ½À(Perineural invasion): ¾øÀ½
¹Ì¼¼¼®È¸È­(Microcalcification): Á¸Àç
¸é¿ªÁ¶Á÷È­ÇÐ °Ë»ç(Immunohistochemistry): Ãß°¡ º¸°í¼­¿¡ µû¸§
Ãß°¡ º¸°í¼­(2024³â 3¿ù 20ÀÏÀÚ)ÀÇ °á°ú:
¿¡½ºÆ®·Î°Õ ¼ö¿ëü(ER): ¾ç¼º(80%, Áß°£ °­µµ), Allred Á¡¼ö 7: °­µµ 2 + ºñÀ² 5
ÇÁ·Î°Ô½ºÅ×·Ð ¼ö¿ëü(PR): ¾ç¼º(80%, °­ÇÑ °­µµ), Allred Á¡¼ö 8: °­µµ 3 + ºñÀ² 5
HER2: À½¼º(Á¡¼ö 0)
E-cadherin: ¾ç¼º
Ki-67 : 25%
¼öÁ¤»èÁ¦´äº¯ÀÛ¼º¸ñ·Ï
¹øÈ£
Á¦¸ñ
ÀÛ¼ºÀÚ
ÀÛ¼ºÀÏ
Á¶È¸
53333
¿µ¾çÁ¦ ¹®ÀÇ ~
ÇÝÇÇ 2024-04-20 137
53332
¿µ¾çÁ¦ ¹®ÀÇ ~
2024-04-22 211
53331
»ïÁßÀ½¼º ±¹¼ÒÀç¹ß Ç׾Ͼ࿡ ´ëÇØ ¹®Àǵ帳´Ï´Ù.
ÀºÇý 2024-04-20 144
53330
»ïÁßÀ½¼º ±¹¼ÒÀç¹ß Ç׾Ͼ࿡ ´ëÇØ ¹®Àǵ帳´Ï´Ù.
2024-04-22 172
53329
Àú¹ßÇö ÇãÅõ
¼Ò¸ÁÀÌ 2024-04-19 151
53328
Àú¹ßÇö ÇãÅõ
2024-04-22 152
53327
¼±Ç×¾Ï, ¼ö¼ú, È丷,´Á¸·,Æó,¸²ÇÁ ÀüÀÌ, Ç×¾Ï ÁßÀÌ¿¡¿ä,,
±è¿¬¿ì 2024-04-19 151
53326
¼±Ç×¾Ï, ¼ö¼ú, È丷,´Á¸·,Æó,¸²ÇÁ ÀüÀÌ, Ç×¾Ï ÁßÀÌ¿¡¿ä,,
2024-04-19 290
53325
Ÿ¸ñ½ÃÆæ
Ç®ÀÙÀ̽½ 2024-04-17 211
53324
Ÿ¸ñ½ÃÆæ
2024-04-18 341
53323
kiÁö¼ö
2024-04-17 377
53322
ÇãÅõ¾ç¼ºÀ¯¹æ¾Ï ÀüÀÌȯÀÚÀÔ´Ï´Ù
±è¼öÁø 2024-04-16 156
53321
ÇãÅõ¾ç¼ºÀ¯¹æ¾Ï ÀüÀÌȯÀÚÀÔ´Ï´Ù
2024-04-17 313
53320
ÇãÅõ¾ç¼ºÀä~
±Ô¸® 2024-04-16 154
12345678910+10¸¶Áö¸·
 
ÀÛ¼º¸ñ·Ï